Turalio risk evaluation and mitigation strategy for treatment of tenosynovial giant cell tumor: framework and experience
Author:
Affiliation:
1. Daiichi Sankyo, Inc. 211, Mt. Airy Rd., Basking Ridge, NJ 07920, USA
2. Vanderbilt-Ingram Cancer Center 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN 37232, USA
Abstract
Funder
Daiichi Sankyo, Inc.
Publisher
Future Medicine Ltd
Subject
Cancer Research,Oncology,General Medicine
Link
https://www.futuremedicine.com/doi/pdf/10.2217/fon-2021-1475
Reference39 articles.
1. Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe
2. U.S. Food and Drug Administration. A Framework for Benefit-Risk Counseling to Patients About Drugs with a REMS. www.fda.gov/media/107591/download Accessed 2 September 2021.
3. U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategies (REMS). www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems (Accessed 2 September 2021).
4. U.S. Food and Drug Administration. What's in a REMS. www.fda.gov/drugs/risk-evaluation-and-mitigation-strategies-rems/whats-rems (Accessed 2 September 2021).
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Exploring the Effect of Compound Glycyrrhizin and Silybinin on the Metabolism of Pexidartinib in Rats Based on CYP3A4 and CYP2C9;Advances in Pharmacological and Pharmaceutical Sciences;2023-12-01
2. The MOTION study: a randomized, Phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor;Future Oncology;2023-08-18
3. Targeting CSF-1R represents an effective strategy in modulating inflammatory diseases;Pharmacological Research;2023-01
4. Targeted therapy;Medicines for Cancer;2023
5. Complementary Effects of Surgery and Pexidartinib in the Management of Patients with Complex Diffuse-Tenosynovial Giant Cell Tumor;Case Reports in Orthopedics;2022-12-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3